Reduction of nitric oxide level enhances the radiosensitivity of hypoxic non-small cell lung cancer

Cancer Science

Volumn 102, Issue 12, 2011, Pages 2150-2156

  Saleem, Wael ^a   Suzuki, Yoshiyuki ^a   Mobaraki, Abdulelah ^a   Yoshida, Yukari ^a   Noda, Shinei ^a   Saitoh, Jun Ich ^a   Nakano, Takashi ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; N(G) METHYLARGININE; NITRIC OXIDE; OXYGEN; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE 1; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CELL METABOLISM; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; NITRIC OXIDE; OMEGA-N-METHYLARGININE; OXYGEN; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 81855213134     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02095.x     Document Type: Article

References (45)

1. Scagliotti GV, Selvaggi G, Novello S et al. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004; 10: 4227s-32s.
2. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis and radiosensitivity in squamous cell carcinomas of head and neck. Cancer Res 1999; 59: 1935-40.
3. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of head and neck. N Engl J Med 2006; 354: 567-78.
4. Sartor CI. Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin Radiat Oncol 2003; 13: 22-30.
5. Giatromanolaki A, Koukourakis MI, Sivridis E et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001; 85: 881-90.
6. Swinson DE, Jones JL, Cox G et al. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer 2004; 111: 43-50.
7. Papandreou I, Cairns RA, Fontana L et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3: 187-97.
8. Kim JW, Tchernyshyov I, Semenza GL et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-85.
9. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002; 64: 993-8.
10. Ignarro LJ, Byrns RE, Buga GM et al. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 1987; 61: 866-79.
11. Palmer RM, Ferrige A, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
12. McKinney LC, Aquilla EM, Coffin D et al. Ionizing radiation potentiates the induction of nitric oxide synthase by IFN-gamma and/or LPS in murine macrophage cell lines: role of TNF-alpha. J Leukoc Biol 1998; 64: 459-66.
13. Cleeter MW, Cooper JM, Darley-Usmar VM et al. Reversible inhibition of cytochrome c oxidase, the terminalenzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett 1994; 345: 50-4.
14. Hagen T, Taylor CT, Lam F et al. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 2003; 302: 1975-8.
15. Brown GC, Cooper CE. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen atcytochrome oxidase. FEBS Lett 1994; 356: 295-8.
16. Bolanos JP, Peuchen S, Heales SJ et al. Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. J Neurochem 1994; 63: 910-6.
17. Juang HH. Nitroprusside stimulates mitochondrial aconitase gene expression through the cyclic adenosine 3', 5'-monosphosphate signal transduction pathway in human prostate carcinoma cells. Prostate 2004; 61: 92-102.
18. Laderoute KR, Grant TD, Murphy BJ et al. Enhanced epidermal growth factor receptor synthesis in human squamous carcinoma cells exposed to low levels of oxygen. Int J Cancer 1992; 52: 428-32.
19. Nishi H, Nishi KH, Johnson AC. Early Growth Response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. Cancer Res 2002; 62: 827-34.
20. Lo HW, Hsu SC, Ali-Seyed M et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005; 7: 575-89.
21. Sandau KB, Fandrey J, Brüne B. Accumulation of HIF-1alpha under the influence of nitric oxide. Blood 2001; 97: 1009-15.
22. Quintero M, Brennan PA, Thomas GJ et al. Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1alpha in cancer: role of free radical formation. Cancer Res 2006; 66: 770-4.
23. Kirito K, Hu Y, Komatsu N. HIF-1 prevents the overproduction of mitochondrial ROS after cytokine stimulation through induction of PDK-1. Cell Cycle 2009; 8: 2844-9.
24. 2 sensing. J Biol Chem 2000; 275: 25130-8.
25. Schroedl C, McClintock DS, Budinger GR et al. Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 2002; 283: 922-31.
26. Guzy RD, Hoyos B, Robin E et al. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 2005; 1: 401-8.
27. Njoku CJ, Patrick KS, Ruiz P Jr et al. Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis. J Investig Med 2005; 53: 347-52.
28. Pearlstein DP, Ali MH, Mungai PT et al. Role of mitochondrial oxidant generation in endothelial cell responses to hypoxia. Arterioscler Thromb Vasc Biol 2002; 22: 566-73.
29. Palacios-Callender M, Quintero M, Hollis VS et al. Endogenous NO regulates superoxide production at low oxygen concentrations by modifying the redox state of cytochrome c oxidase. Proc Natl Acad Sci USA 2004; 101: 7630-5.
30. Brown GC. Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase. Biochim Biophys Acta 2001; 1504: 46-57.
31. Cooper CE. Nitric oxide and cytochrome oxidase: substrate, inhibitor or effector? Trends Biochem Sci 2002; 27: 33-9.
32. Yabuki M, Tsutsui K, Horton AA et al. Caspase activation and cytochrome c release during HL-60 cell apoptosis induced by a nitric oxide donor. Free Radic Res 2000; 32: 507-14.
33. Moriya R, Uehara T, Nomura Y. Mechanism of nitric oxide-induced apoptosis in human neuroblastoma SH-SY5Y cells. FEBS Lett 2000; 484: 253-60.
34. Li J, Bombeck CA, Yang S et al. Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. J Biol Chem 1999; 274: 17325-33.
35. Levesque MC, Ghosh DK, Beasley BE et al. CLL cell apoptosis induced by nitric oxide synthase inhibitors: correlation with lipid solubility and NOS1 dissociation constant. Leuk Res 2008; 32: 1061-70.
36. Brown JM, Wouters BG. Does apoptosis contribute to tumor cell sensitivity to anticancer agents? In: Hickman JA, Dive C, eds. Apoptosis and Cancer Chemotherapy. Totowa, NJ, USA: Humana Press, 1999; 1-20.
37. Waldman T, Zhang Y, Dillehay L et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997; 3: 1034-6.
38. Viktorsson K, Heiden T, Molin M, Akusjärvi G, Linder S, Shoshan MC. Increased apoptosis and increased clonogenic survival of 12V-H-ras transformed rat fibroblasts in response to cisplatin. Apoptosis 2000; 5: 355-67.
39. Swinson DE, O'Byrne KJ. Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. Clin Lung Cancer 2006; 7: 250-6.
40. Tracy S, Mukohara T, Hansen M et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004; 64: 7241-4.
41. Lammering G, Valerie K, Lin PS et al. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 2004; 72: 267-73.
42. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-92.
43. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
44. Mendelsohon J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-99.
45. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990; 265: 7709-12.